Introduction
============

Psoriatic arthritis (PsA) is an inflammatory disease affecting joints and connective tissues.[@b1-btt-6-417] PsA affects up to 30% of individuals with psoriasis, a chronic skin condition affecting 1%--2% of the general population.[@b1-btt-6-417] It can be a destructive disabling joint disease, with the severity increasing over time.[@b1-btt-6-417] There are no cures for PsA and so the focus of treatment has been on controlling symptoms and preventing damage to joints. Patients are typically treated first with nonsteroidal anti-inflammatory drugs (NSAIDS), that help to reduce pain and inflammation of the joints.[@b2-btt-6-417] In patients with more severe disease, disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, are often a first course of treatment.[@b2-btt-6-417] More recently, therapies that inhibit the pro-inflammatory protein -- tumor necrosis factor (TNF) -- are increasingly being used in patients who have failed traditional DMARD therapy.[@b2-btt-6-417]

Currently, four anti-TNFs are indicated for the treatment of PsA in combination with methotrexate (MTX). So far two comparative effectiveness assessments of available anti-TNFs for PsA have been conducted, both in connection with a health technology assessment (HTA).[@b3-btt-6-417],[@b4-btt-6-417] However, because of methodological shortcomings and limitations, the inferences from these analyses are weakened. The first HTA included adjusted indirect comparisons of only three of the four indicated anti-TNFs (adalimumab, infliximab, and etanercept).[@b3-btt-6-417] In addition, although this HTA provided summary tables of the trial outcomes at different time points (eg, 14 weeks and 24 weeks), it was not clear which time points were used for producing the pooled comparative effectiveness estimates. The second HTA attempted to model only a few outcomes that lend themselves well to an economic model (ie, PsA response criteria \[PsARC\], Health Assessment Questionnaire \[HAQ\] by PsARC responders and nonresponders, and Psoriasis Area and Severity Index \[PASI\] mean change as a continuous variable).[@b4-btt-6-417] However, the shortage in available data on these outcomes led the authors to conduct what was effectively a Bayesian imputation analysis. Given the scarcity of the data used, it is evident that the effectiveness estimates and any accompanying cost-effectiveness estimates will be sensitive to the imputation assumptions, and that the "noninformative" priors elicited in the model may carry a relatively high degree of information, and thus bias the estimates of effect.[@b5-btt-6-417],[@b6-btt-6-417]

To address the shortcomings of previous indirect comparisons, and in particular the most recent HTA report, we performed an exhaustive literature search and data extraction of all trial publications, data available in published meta-analyses, and data available from HTAs. We used all available data on outcomes to calculate previously missing trial results, and thereby obviated the shortcomings of the Bayesian approach. We then re-ran the indirect comparison to obtain "improved" estimates of effect on the outcomes used to derive quality-adjusted life year (QALY) estimates in a recent National Institute for Health and Clinical Excellence (NICE) HTA.[@b4-btt-6-417]

Methods
=======

Eligibility criteria
--------------------

We included randomized controlled trials (RCTs) examining the efficacy of anti-TNF biological agents (adalimumab, etanercept, golimumab, and infliximab) for the treatment of PsA. RCTs studying adult populations with active and progressive PsA with an inadequate response to previous DMARD therapy were eligible. We included RCTs of any treatment dose and duration of the above-specified anti-TNF biologics. We excluded trials conducted among PsA populations that had an adequate response to DMARD therapy, or were naïve to DMARD therapy. We also excluded trials conducted among PsA populations with prior experience with anti-TNF agents, including an inadequate response. Furthermore, trials that did not have a placebo control and that examined non-anti-TNF biological agents were excluded.

Search strategy
---------------

In consultation with a medical librarian, two investigators (ED, KT) independently conducted a systematic literature search for RCTs. The search terms included "psoriatic arthritis," " biologic," "anti-TNF," and the generic and brand names of each of the agents (eg, "adalimumab," "etanercept," "golimumab," "infliximab"). The following electronic databases (from inception to week 15 \[April 9--15\], 2012) were searched: MEDLINE, EMBASE, and Cochrane CENTRAL. Searches were limited to RCTs in humans, but not limited by language. Additionally, we searched for published HTAs and systematic reviews to further identify completed RCTs and/or obtain additional data on the published clinical trials. Lastly, some additional data were provided by Merck-Shire-Dome, UK. The exact search strategy is available from the authors upon request.

Study selection
---------------

Following the systematic literature searches, the same two investigators (ED, KT) obtained the full manuscripts of relevant trials, and independently assessed the relevance of each to determine whether or not it fit the eligibility criteria listed above. Any discrepancies between the two investigators were resolved by consulting a third investigator (EM) if necessary. Trials that did not meet the eligibility criteria were excluded and their reference listed with reasons for exclusion. Eligible trials underwent a quality assessment by one investigator (ED), using a modified Jadad scale.[@b7-btt-6-417]

Data abstraction
----------------

Data were extracted by one investigator (ED) and independently checked by a second investigator (KT). Disagreements between the data extracted were resolved by consulting a third investigator (EM) if necessary. We abstracted data on anti-inflammatory response as derived from the PsARC. Response of psoriatic skin lesions, as determined by the PASI, was also abstracted. Finally, functional status, as determined by the HAQ score, was abstracted overall, and by PsARC response, where possible. Definitions of each for the outcomes are presented in the [Supplementary materials (Table S1)](#s1-btt-6-417){ref-type="supplementary-material"}. The following trial characteristics were also abstracted: study design, number of subjects, trial duration, outcome measures used, treatment dose and duration, concomitant therapies, and participant characteristics.

Data synthesis
--------------

### Outcomes

We considered the same three outcomes as a previous HTA: the PsARC response, the HAQ mean change from baseline for PsARC responders and nonresponders, and the PASI mean change from baseline. Our primary endpoint was the last observed time point in the trial, before allowed dose escalation or treatment cross-over. We chose this because patients with escalated dose and patients that have crossed over are no longer comparable to patients on a fixed dose treatment in terms of estimating efficacy.

### Dealing with incomplete data

The PsARC response was reported completely across all trial publications, and thus did not require any transformations or imputations. The HAQ mean change by PsARC responders and non-responders were made available to us through the full version of a recently published HTA.[@b4-btt-6-417] However, the HAQ scores from the Mease 2000[@b8-btt-6-417] and Mease 2004[@b9-btt-6-417] studies had been combined in this HTA, and the available placebo HAQ response had been compiled across Mease 2000, Mease 2004, and the IMPACT trials.[@b16-btt-6-417]--[@b18-btt-6-417] For this reason we made use of the overall HAQ baseline and mean change scores extracted from the trial publications to calculate the summary statistics which were not reported (note all missing data points were fully derived and no imputations were needed). [Table S2](#s2-btt-6-417){ref-type="supplementary-material"} provides a detailed overview of necessary data conversions for the HAQ outcome.

For the PASI mean change only IMPACT and IMPACT 2 had complete data. For the remaining trials except for Mease 2004, baseline PASI and associated standard deviations (SDs) as well as PASI50, PASI70, and PASI90 were available. We assumed that the absolute percentage mean change approximately followed a normal distribution and approximated the mean and standard deviation from the PASI50, PASI70, and PASI90 data. We then used the approximated distribution with the available baseline distribution to produce PASI mean changes, using simulations. For Mease 2004, where no baseline data was available, we imputed data by random sampling from the other trials. Appendix 2 provides a detailed overview of necessary data conversions and imputations for the PASI outcome.

### Statistical models

We performed frequentist indirect comparison meta-analyses using random-effects models.[@b13-btt-6-417] We obtained comparative relative risks (RR) with 95% confidence intervals for PsARC, and mean difference (MD) estimates with 95% confidence intervals for HAQ (PsARC responders and nonresponders) and PASI. All analyses were performed using StatsDirect (StatsDirect Ltd, Altrincham, UK) and R v. 2.14 (The R Project for Statistical Computing; <http://www.R-project.org/>).

For PsARC we pooled the response rate in the placebo group from all trials, and used simulation to produce the expected response rate with each of the treatments using the indirect RR estimates and associated (log) standard error estimates. For HAQ and PASI we pooled the control group mean responses from baseline across trials, and used simulation to produce the expected mean response with each of the treatments using the indirect MD estimates and associated standard error estimates. Our primary analysis was of the outcomes observed at last time point (before allowed dose escalation or cross-over). However, since the last observed time points across trials were not consistent, we performed sensitivity analysis where possible. For PsARC we performed sensitivity analysis using similar "short-term" (ie, 12--16 weeks) outcomes, and, separately, "long-term" (ie, 24 weeks) outcomes where available. These analyses were not possible for the HAQ and PASI outcomes as we only had data on one time point.

Results
=======

Identified studies
------------------

Nineteen studies, representing seven RCTs, met our inclusion criteria.[@b14-btt-6-417]--[@b27-btt-6-417] Two of these RCTs used adalimumab,[@b14-btt-6-417]--[@b19-btt-6-417] two used etanercept,[@b8-btt-6-417]--[@b27-btt-6-417] two used infliximab,[@b10-btt-6-417]--[@b24-btt-6-417] and one used golimumab.[@b20-btt-6-417][Table 1](#t1-btt-6-417){ref-type="table"} presents the characteristics of each RCT, and [Table S3](#s3-btt-6-417){ref-type="supplementary-material"} presents the demographic characteristics of the patients included in each RCT. Twenty-nine studies examined in detail were excluded; reasons for exclusion are presented in [Table S4](#s4-btt-6-417){ref-type="supplementary-material"}. A schematic of the study selection process is presented in [Figure 1](#f1-btt-6-417){ref-type="fig"}.

Indirect comparisons
--------------------

For all treatments for all outcomes (except for adalimumab for HAQ nonresponders), there was a statistically significant difference in favor of the treatment (allowing for 5% type I error).

[Figure 2](#f2-btt-6-417){ref-type="fig"} presents the direct estimates for each of the anti-TNF treatments compared with placebo. For PsARC response, golimumab yielded the highest relative risk (RR 3.45, 95% CI: 2.39, 4.99) and etanercept the second highest (RR 3.19, 95% CI: 2.31, 4.42). Adalimumab and infliximab both yielded notably smaller RRs. Sensitivity analysis using different time points did not reveal any difference in PsARC response RRs (results not shown, but available from the authors upon request). For HAQ improvement, etanercept and infliximab yielded the largest MD among PsARC responders (0.43 and 0.41, respectively). For PsARC nonresponders, etanercept, infliximab, and golimumab yielded similar MDs, and adalimumab yielded a notably lower MD. For PASI improvement, infliximab yielded the largest MD and golimumab the second largest (6.44 and 4.90, respectively), while etanercept yielded the smallest MD (3.13).

[Table 2](#t2-btt-6-417){ref-type="table"} presents the indirect estimates between anti-TNF treatments. None of the four treatments were statistically significantly different for any of the outcomes.

Lastly, [Table 3](#t3-btt-6-417){ref-type="table"} presents the pooled control group responses and the expected intervention group responses using the indirect RR and MD estimates from the placebo comparison.

Discussion
==========

Our indirect comparison of anti-TNF drugs for PsA was based on an extensive literature search and data extraction that allowed us to calculate trial results that were missing in previous indirect comparisons. No statistically significant difference was detected between the four anti-TNF drugs. When considering only the magnitude of estimated effect, the three anti-TNF drugs etanercept, infliximab, and golimumab seem to perform comparably better than adalimumab. When compared with each other, each of these three anti-TNFs performed better for one or two outcomes, but worse for one or two other outcomes (eg, golimumab yields the highest PsARC response, but the lowest average HAQ among PsARC nonresponders). In some instances, the treatment effect point estimates were also notably different from the estimates used to inform the recent NICE cost-effectiveness analysis.[@b4-btt-6-417]

Our indirect comparison comes with a number of strengths and limitations. We performed an extensive search of all trial publications (several reports have been published for each trial[@b14-btt-6-417]--[@b29-btt-6-417]), previous systematic reviews, and HTAs. This allowed us to extract enough data to calculate the results of the outcomes of interest when missing. This also removed the necessity for Bayesian imputation models driven by priors. Despite the extensive data search and extraction, one cannot avoid the fact that the trial data are relatively sparse. Thus, calculations made for missing values and inferences regarding comparative effectiveness may be considerably impacted by random error. Some data may also have been suboptimal. For HAQ improvement by PsARC responders, our etanercept data were a pooled analysis of the Mease 2000 and Mease 2004 trials. Although we were able to use trial reported HAQ scores to calculate and validate these results, some bias concerns exist with regards to Mease 2000, which we were not able to perform sensitivity analysis on. For PASI improvement, we only had continuous data available for about half of the trials. The conversion based on reported PASI50, PASI75, and PASI90 is only approximate, and may thus introduce some error. However, we do not believe this potential error is worse than the bias introduced by using falsely labeled "noninformative" priors in a Bayesian imputation model.

This incongruence between magnitudes of effect estimates in our indirect comparison and previous indirect comparisons, strongly suggests sensitivity to analytic approaches that should not be overlooked in related economic evaluations. Patient utility can be derived by already established mathematical relationships between generic quality of life instruments such as the EQ-5D and the disease outcomes of interest (PsARC, HAQ, and PASI). While previous health economic assessments did perform a wide array of sensitivity analyses, these did not cover sensitivity to different analytic approach such as the 'imputation' used for our indirect comparison. Given that adalimumab, etanercept, golimumab, and infliximab are approved for use in PsA in many major settings, it is unlikely that we will see additional trials assessing the efficacy of these therapies, and so, economic evaluations will need to rely on the current available evidence. As such, it seems important to undertake a revision of current cost-effectiveness models to assess whether current drug indications are based on robust results, or need reconsideration.

Conclusion
==========

Our indirect comparison did not demonstrate any significant difference between anti-TNF drugs for the treatment of PsA. In some instances, the magnitudes of effect in our indirect comparison differed from others. Since the analyzed outcomes play an important role informing quality adjusted life years (QALYs, and thus cost per QALY) in cost-effectiveness analyses, it seems reasonable to insist that the cost-effectiveness analyses on which the current drug indications are based be revised to check the robustness of their findings.

Supplementary materials
=======================

###### 

Outcomes included in the analysis

  Outcome                                         Definition
  ----------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Psoriatic arthritis response criteria (PsARC)   PsARC is defined as an improvement in at least two of the following four measures: patient self-assessment, physician assessment, joint pain/tenderness score, and joint swelling score. One of the two measures must be joint pain/tenderness score or joint swelling score. No worsening can occur in any of the four measures.
  Psoriasis area and severity index (PASI)        PASI combines the assessment of the severity of lesions and the area affect into a score that spans from 0 (no disease) to 72 (maximal disease). At least 3% of the body surface area has to be affected by the psoriasis in order for the PASI measure to be used.
  Health assessment questionnaire (HAQ)           The HAQ focuses on two dimensions of health status: physical disability and pain, generating a score of 0 (least disability) to 3 (most severe disability).

###### 

Imputations solutions and assumptions employed to construct PASI mean changes

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                           Data format                                                        Imputation solutions and employed assumptions
  ----------------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Mease et al[@b13-btt-6-417]                     Baseline median and range (assumed range = 2 × 3 SEs)\             Assume similar percentage change SD as Mease 2004\
                                                  Percentage change from baseline                                    Assume mean percentage change is normally distributed\
                                                                                                                     Simulate PASI mean change scores from available baseline and % change data

  Mease et al[@b25-btt-6-417]--[@b27-btt-6-417]   Baseline not reported\                                             Assume similar baseline score as Mease 2000\
                                                  Percentage change (SE)                                             Assume mean percentage change is normally distributed\
                                                                                                                     Simulate PASI mean change scores from assumed baseline and available % change data

  IMPACT[@b10-btt-6-417]--[@b12-btt-6-417]        PASI (BSA \> 3%) reported by PsARC responders and nonresponders    Take weighted average of PsARC responders and nonresponders

  IMPACT 2[@b21-btt-6-417]--[@b24-btt-6-417]      PASI (BSA \> 3%) reported by PsARC responders and nonresponders    Same as IMPACT

  ADEPT[@b14-btt-6-417]--[@b18-btt-6-417]         Baseline PASI mean and SE\                                         Assume percentage change is normally distributed\
                                                  Percentage achieving 50%, 75%, and 90%\                            Approximate normal distribution mean and SE using available percentiles (PASI50, PASI75, and PASI90 transformed)\
                                                  PASI improvement                                                   Simulate PASI mean change scores from assumed baseline and available % change data

  GO-REVEAL[@b20-btt-6-417]                       PASI (BSA \> 3%) reported by PsARC responders and non-responders   Same as IMPACT
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; BSA, body surface area; GO-REVEAL, Golimumab-Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria; SD, standard deviation; SE, standard error.

###### 

Demographic characteristics of participants in the included randomized controlled trials

                                            Mease[@b8-btt-6-417]                             Mease[@b9-btt-6-417],[@b25-btt-6-417]--[@b27-btt-6-417]   IMPACT[@b10-btt-6-417]--[@b12-btt-6-417]           IMPACT 2[@b21-btt-6-417]--[@b24-btt-6-417]         ADEPT[@b14-btt-6-417]--[@b18-btt-6-417]                                                      Genovese et al[@b19-btt-6-417]                                                               GO-REVEAL[@b20-btt-6-417]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ----------------------------------------- ------------------------------------------------ --------------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  Patients randomized, no                   30                                               30                                                        101                                                104                                                52                                                                                           52                                                                                           100                                                                                          100                                                                                          151                                                                                            162                                                                                            51                                                                                             49                                                                                             146                                                                                          146                                                                                          113
  Male sex, %                               53                                               60                                                        57                                                 45                                                 58                                                                                           58                                                                                           71                                                                                           51                                                                                           56                                                                                             55                                                                                             57                                                                                             51                                                                                             61                                                                                           59                                                                                           61
  Caucasian, %                              90                                               83                                                        90                                                 91                                                 --                                                                                           --                                                                                           --                                                                                           --                                                                                           97                                                                                             94                                                                                             98                                                                                             94                                                                                             97                                                                                           97                                                                                           97
  Age, years                                46.0[\*](#tfn7-btt-6-417){ref-type="table-fn"}   43.5[\*](#tfn7-btt-6-417){ref-type="table-fn"}            47.6[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}   47.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}   45.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             45.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             47.1[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             46.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             48.6[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               49.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               50.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               47.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               45.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             48.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             47.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}
  Psoriasis duration, years                 19.0[\*](#tfn7-btt-6-417){ref-type="table-fn"}   17.5[\*](#tfn7-btt-6-417){ref-type="table-fn"}            18.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}   19.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}   16.9[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             19.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             NS                                                                                           NS                                                                                           17.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               17.1[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               18.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               13.8[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                               NS                                                                                           NS                                                                                           NS
  PsA duration, years                       9.0[\*](#tfn7-btt-6-417){ref-type="table-fn"}    9.5[\*](#tfn7-btt-6-417){ref-type="table-fn"}             9.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}    9.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}    11.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             11.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                             8.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                              7.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                              9.8[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                9.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                7.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                7.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                7.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                              7.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                              7.6[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}
  PsA type, %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Distal interphalangeal joint arthritis   NS                                               NS                                                        51                                                 50                                                 NS                                                                                           NS                                                                                           NS                                                                                           NS                                                                                           10                                                                                             5                                                                                              6                                                                                              0                                                                                              16                                                                                           15                                                                                           14
   Arthritis mutilans                       NS                                               NS                                                        1                                                  2                                                  NS                                                                                           NS                                                                                           NS                                                                                           NS                                                                                           1                                                                                              0                                                                                              0                                                                                              0                                                                                              1                                                                                            1                                                                                            0
   Asymmetric peripheral arthritis          NS                                               NS                                                        41                                                 38                                                 NS                                                                                           NS                                                                                           NS                                                                                           NS                                                                                           25                                                                                             25                                                                                             10                                                                                             14                                                                                             30                                                                                           34                                                                                           24
   Polyarticular arthritis                  NS                                               NS                                                        86                                                 83                                                 100                                                                                          100                                                                                          NS                                                                                           NS                                                                                           64                                                                                             70                                                                                             82                                                                                             84                                                                                             43                                                                                           38                                                                                           51
   Ankylosing spondylitis                   NS                                               NS                                                        3                                                  4                                                  NS                                                                                           NS                                                                                           NS                                                                                           NS                                                                                           1                                                                                              0                                                                                              2                                                                                              2                                                                                              10                                                                                           12                                                                                           11
  Swollen joint count                       NS                                               NS                                                        NS                                                 NS                                                 14.6[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   14.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   13.9[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   14.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   14.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   14.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   18.2[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   18.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   14.1[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   12.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   13.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}
  Tender joint count                        NS                                               NS                                                        NS                                                 NS                                                 23.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   20.4[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   24.6[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   25.1[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   22.7[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   19.1[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   29.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   25.3[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[††](#tfn10-btt-6-417){ref-type="table-fn"}   24.0[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   22.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}   21.9[\*\*](#tfn8-btt-6-417){ref-type="table-fn"},[†](#tfn9-btt-6-417){ref-type="table-fn"}
  Prior number of DMARDs                    1.5[\*](#tfn7-btt-6-417){ref-type="table-fn"}    2.0[\*](#tfn7-btt-6-417){ref-type="table-fn"}             NS                                                 NS                                                 NS                                                                                           NS                                                                                           NS                                                                                           NS                                                                                           1.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                1.5[\*\*](#tfn8-btt-6-417){ref-type="table-fn"}                                                NS                                                                                             NS                                                                                             NS                                                                                           NS                                                                                           NS
  Concomitant therapies during study, %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Corticosteroid                           20                                               40                                                        19                                                 15                                                 NS                                                                                           NS                                                                                           10                                                                                           15                                                                                           NS                                                                                             NS                                                                                             8                                                                                              18                                                                                             13                                                                                           18                                                                                           17
   NSAID                                    67                                               77                                                        88                                                 83                                                 NS                                                                                           NS                                                                                           73                                                                                           71                                                                                           NS                                                                                             NS                                                                                             73                                                                                             86                                                                                             75                                                                                           75                                                                                           78
   MTX                                      47                                               47                                                        42                                                 41                                                 NS                                                                                           NS                                                                                           45                                                                                           47                                                                                           51                                                                                             50                                                                                             47                                                                                             47                                                                                             49                                                                                           47                                                                                           48

**Notes:**

Median;

mean;

0--66 (swollen joints), 0--68 (tender joints);

0--76 (swollen joints), 0--78 (tender joints).

**Abbreviations:** ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; ADA, adalimumab; DMARDs, disease-modifying antirheumatic drugs; ETN, etanercept; GOL, golimumab; GO-REVEAL, Golimumab-Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; INF, inflizimab; MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drugs; PsA, psoriatic arthritis; NS, not stated.

###### 

Publications excluded after detailed evaluation

  Study                                   Reason for exclusion
  --------------------------------------- --------------------------------------------------------------------------------------------------------
  Baranauskaite et al[@b28-btt-6-417]     Included patients naïve to methotrexate
  Kimball et al[@b29-btt-6-417]           Does not exclusively include psoriatic arthritis patients; sub-analysis to randomized controlled trial
  Mease et al[@b30-btt-6-417]             Treatment not of interest; included inadequate responders to adalimumab, entanercept, or infliximab
  Prinz et al[@b31-btt-6-417]             Does not include a control arm; post hoc analysis to randomized controlled trial
  Asahina et al[@b32-btt-6-417]           Does not exclusively include psoriatic arthritis patients
  Atteno et al[@b33-btt-6-417]            Not a randomized controlled trial
  Mease et al[@b34-btt-6-417]             Pooled analyses of randomized controlled trials
  Sterry et al[@b35-btt-6-417]            Does not include a control arm
  Torii et al[@b36-btt-6-417]             Does not exclusively include psoriatic arthritis patients
  Van Kuijk et al[@b37-btt-6-417]         Does not include outcomes of interest
  Bongiorno et al[@b38-btt-6-417]         Not a randomized controlled trial
  Brodszky et al[@b39-btt-6-417]          Not a randomized controlled trial
  Feldman et al[@b40-btt-6-417]           Does not exclusively include psoriatic arthritis patients
  Kristensen et al[@b41-btt-6-417]        Not a randomized controlled trial
  Ravindran et al[@b42-btt-6-417]         Not a randomized controlled trial
  Revicki et al[@b43-btt-6-417]           Does not exclusively include psoriatic arthritis patients
  Saad et al[@b44-btt-6-417]              Not a randomized controlled trial
  Spadaro et al[@b45-btt-6-417]           Not a randomized controlled trial
  Strober et al[@b46-btt-6-417]           Does not include outcomes of interest
  Frankel et al[@b47-btt-6-417]           Not a randomized controlled trial
  Kimball et al[@b48-btt-6-417]           Not a randomized controlled trial
  Romero-Maté et al[@b49-btt-6-417]       Not a randomized controlled trial
  Vander Cruyssen et al[@b50-btt-6-417]   Not a randomized controlled trial
  Fransen et al[@b51-btt-6-417]           Not a randomized controlled trial
  Gottlieb et al[@b52-btt-6-417]          Not a randomized controlled trial
  Mease et al[@b25-btt-6-417]             Not a randomized controlled trial
  Ritchlin[@b53-btt-6-417]                Not a randomized controlled trial
  Kvien et al[@b54-btt-6-417]             Not a randomized controlled trial
  Rinaldi et al[@b55-btt-6-417]           Not a randomized controlled trial
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###### 

Characteristics of the included trials

  Trial                                           Intervention                              Setting                                      Blinded period   No of patients randomized   Quality score   Outcomes of interest
  ----------------------------------------------- ----------------------------------------- -------------------------------------------- ---------------- --------------------------- --------------- ----------------------
  Mease et al[@b8-btt-6-417]                      ETN (25 mg twice weekly)                  NS                                           12 weeks         60                          5/5             HAQ, PASI, PsARC
  Mease et al[@b25-btt-6-417]--[@b27-btt-6-417]   ETN (25 mg twice weekly)                  17 sites in USA                              24 weeks         205                         4/5             PASI, PsARC
  IMPACT[@b10-btt-6-417]--[@b12-btt-6-417]        INF (5 mg/kg at weeks 0, 2, 6, 14)        9 sites in Europe, Canada, USA               16 weeks         104                         4/5             HAQ, PsARC
  IMPACT 2[@b21-btt-6-417]--[@b24-btt-6-417]      INF (5 mg/kg at weeks 0, 2, 6, 14, 22)    36 sites in Europe, Canada, USA              16 weeks         200                         4/5             HAQ, PASI, PsARC
  ADEPT[@b14-btt-6-417]--[@b18-btt-6-417]         ADA (40 mg every other week)              50 sites in Europe, Australia, Canada, USA   24 weeks         313                         3/5             HAQ, PASI, PsARC
  Genovese et al[@b19-btt-6-417]                  ADA (40 mg every other week)              16 sites in Canada, USA                      24 weeks         100                         5/5             HAQ, PsARC
  GO-REVEAL[@b20-btt-6-417]                       GOL (50 mg or 100 mg every fourth week)   52 sites in Europe, Canada, USA              24 weeks         405                         5/5             HAQ, PASI, PsARC

**Abbreviations:** ADA, adalimumab; ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial; ETN, etanercept; GOL, golimumab; GO-REVEAL, Golimumab-Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; HAQ, Health Assessment Questionnaire; IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; INF, inflizimab; NS, not stated; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria.

###### 

Head-to-head indirect estimates of the anti-TNF drugs

  ------------------------------------------------------------------------------------------------------
  Comparison       PsARC\              HAQ\                  PASI\                 
                   RR (95% CI)         MD (95% CI)           MD (95% CI)           
  ---------------- ------------------- --------------------- --------------------- ---------------------
  ADA versus ETN   0.75 (0.49, 1.24)   −0.23 (−0.51, 0.05)   −0.15 (−0.33, 0.03)   0.98 (−1.72, 3.68)

  ADA versus INF   0.91 (0.53, 1.32)   −0.21 (−0.48, 0.06)   −0.11 (−0.27, 0.05)   −2.33 (−7.30, 2.64)

  ADA versus GOL   0.69 (0.44, 1.26)   −0.03 (−0.33, 0.27)   −0.08 (−0.25, 0.09)   −0.79 (−3.27, 1.69)

  ETN versus INF   1.21 (0.69, 1.34)   0.02 (−0.26, 0.30)    0.04 (−0.15, 0.23)    −3.31 (−8.44, 1.82)

  ETN versus GOL   0.92 (0.57, 1.28)   0.20 (−0.10, 0.50)    0.07 (−0.13, 0.26)    −1.77 (−4.55, 1.01)

  INF versus GOL   0.76 (0.42, 1.35)   0.18 (−0.11, 0.47)    0.03 (−0.15, 0.21)    1.54 (−3.48, 6.56)
  ------------------------------------------------------------------------------------------------------

**Abbreviations:** ADA, adalimumab; anti-TNF, anti-tumor necrosis factor; CI, confidence interval; ETN, etanercept; GOL, golimumab; HAQ, Health Assessment Questionnaire; INF, infliximab; MD, mean difference; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria; RR, relative risk.

###### 

Expected response rates and 95% confidence intervals for the three considered outcomes with the four anti-TNF drugs

  Outcome                             Placebo response    Anti-TNF treatment response                                            
  ----------------------------------- ------------------- ----------------------------- ------------------- -------------------- -------------------
  PsARC response (proportion)         0.25 (0.21, 0.28)   0.60 (0.50, 0.70)             0.80 (0.70, 0.88)   0.66 (0.48, 0.81)    0.86 (0.76, 0.93)
  HAQ responders (mean response)      0.24 (0.18, 0.31)   0.44 (0.29, 0.51)             0.67 (0.47, 0.87)   0.65 (0.47, 0.83)    0.47 (0.24, 0.69)
  HAQ nonresponders (mean response)   0.01 (−0.3, 0.04)   0.09 (−0.02, 0.18)            0.24 (0.10, 0.39)   0.19 (0.09, 0.32)    0.17 (0.04, 0.31)
  PASI (mean response)                0.68 (0.31, 1.04)   4.79 (3.10, 6.48)             3.81 (1.71, 5.91)   7.12 (2.43, 11.78)   5.58 (3.76, 7.40)

**Note:** Confidence intervals are derived assuming a fixed placebo response.

**Abbreviations:** ADA, adalimumab; anti-TNF, anti-tumor necrosis factor; ETN, etanercept; GOL, golimumab; HAQ, Health Assessment Questionnaire; INF, infliximab; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria.
